Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 32.4% from the August 15th total of 42,600 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.9 days.
Bioasis Technologies Stock Performance
BIOAF remained flat at $0.13 during midday trading on Friday. The firm's fifty day moving average is $0.12 and its 200 day moving average is $0.16. Bioasis Technologies has a 52-week low of $0.10 and a 52-week high of $0.28.
Get Bioasis Technologies alerts:About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.Featured Stories
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
